The Mesoblast Ltd (ASX: MSB) share price is in focus after the company reported net revenues of US$30 million for the December 2025 quarter, up 60% from the prior period, on the back of strong Ryoncil® sales and new financing arrangements.
Image source: Getty Images
What did Mesoblast report?
- Ryoncil® gross sales reached US$35 million, a 60% lift quarter-on-quarter
- Net revenues for the quarter totalled US$30 million
- US$130 million in cash on hand at 31 December 2025
- Net operating cash outflow of US$16 million for the quarter
- Secured a US$125 million non-dilutive credit facility at 8% interest, with an unsecured US$75 million tranche drawn
- No interim dividend declared
What else do investors need to know?
Mesoblast enhanced its financial flexibility this quarter, drawing US$75 million from a new lower-cost debt facility. This replaces more expensive loans and gives the company greater room to fund strategic partnerships as well as potential product expansion.
Clinically, Mesoblast provided positive updates on Ryoncil®'s use in paediatric patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD), as well as progress in extending Ryoncil®'s label to treat adults—an addressable market about three times larger. The company also received constructive feedback from the US FDA regarding its chronic low back pain therapy, with pivotal Phase 3 studies close to completing enrolment.
What did Mesoblast management say?
Mesoblast Chief Executive Dr. Silviu Itescu said:
This quarter was highlighted by continued strong Ryoncil® sales and the establishment of a new lower-cost non-dilutive financing facility both of which enable greater flexibility for strategic partnerships and pursuit of label expansion for Ryoncil®.
What's next for Mesoblast?
Looking ahead, Mesoblast expects net cash outflows to decline, driven by stable or growing product revenues and tight cost controls. The company aims to complete the pivotal trial for Ryoncil® in adults and finish key patient enrolment in its chronic low back pain program during the next quarter.
Management also flagged its plans to pursue new regulatory submissions and further manufacturing scale-up, as it seeks to establish additional cell therapies for inflammatory conditions. Strategic partnerships and global commercial expansion remain key sections of Mesoblast's long-term roadmap.
Mesoblast share price snapshot
Over the past 12 months, Mesoblast shares have declined 12%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.
